104 related articles for article (PubMed ID: 17933133)
21. [Current status in and future directions of the treatment of hematological disorders with molecular-targeting agents--Overview].
Kizaki M
Rinsho Ketsueki; 2011 Aug; 52(8):583-6. PubMed ID: 21897063
[No Abstract] [Full Text] [Related]
22. A case of chronic myelogenous leukemia with e8a2 fusion transcript.
Park IJ; Lim YA; Lee WG; Park JS; Kim HC; Lee HJ; Cho SR
Cancer Genet Cytogenet; 2008 Sep; 185(2):106-8. PubMed ID: 18722880
[TBL] [Abstract][Full Text] [Related]
23. Chronic myelogenous leukemia: the new paradigm.
Winn RJ
J Natl Compr Canc Netw; 2003 Oct; 1(4):455. PubMed ID: 19774737
[No Abstract] [Full Text] [Related]
24. BCR-ABL in chronic myelogenous leukemia--how does it work?
Goldman JM; Melo JV
Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of chronic myeloid leukemia. Uncommon view of the modern approaches].
Mayer J; Zácková D; Klamová H; Doubek M
Cas Lek Cesk; 2008; 147(4):206-10. PubMed ID: 18578373
[TBL] [Abstract][Full Text] [Related]
26. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism.
Zhang SJ; Shi JY; Li JY
Leuk Res; 2009 Aug; 33(8):1141-3. PubMed ID: 19304323
[TBL] [Abstract][Full Text] [Related]
27. Recent publications in hematological oncology.
Hematol Oncol; 2007 Sep; 25(3):148-55. PubMed ID: 17957827
[No Abstract] [Full Text] [Related]
28. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of hematologic neoplasms during pregnancy].
Tartas NE; Foncuberta MC; Avalos JC
Medicina (B Aires); 2007; 67(6 Pt 2):729-36. PubMed ID: 18422070
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
31. Ultrastructural characteristics of bone marrow in patients with hematological disease: a study of 13 cases.
Ru YX; Zhao SX; Liu EB; Yang QY; Liu JH; Pang TX; Chen HS
Ultrastruct Pathol; 2007; 31(5):327-32. PubMed ID: 17963181
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement.
Ziogas DC; Zintzaras E
Ann Epidemiol; 2009 Jul; 19(7):494-500. PubMed ID: 19523596
[TBL] [Abstract][Full Text] [Related]
33. Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor.
Cutting RJ; Welch E; Channer J; Ezaydi Y; Talley P; Reilly JT; Snowden JA
Bone Marrow Transplant; 2008 Nov; 42(9):631-3. PubMed ID: 18695662
[No Abstract] [Full Text] [Related]
34. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
[TBL] [Abstract][Full Text] [Related]
35. Malignant diseases of the blood.
Haurani FI; Thorling KH
Pa Med; 1966 Nov; 69(11):33-6. PubMed ID: 5342122
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
[TBL] [Abstract][Full Text] [Related]
37. Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Komarova NL; Wodarz D
Cancer Res; 2009 Jun; 69(11):4904-10. PubMed ID: 19458080
[TBL] [Abstract][Full Text] [Related]
38. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
39. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Jabbour E; Cortes J; Giles F; Kantarjian H
Cancer J; 2007; 13(6):357-65. PubMed ID: 18032972
[TBL] [Abstract][Full Text] [Related]
40. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
